Zura Bio's (ZURA) Sell (D-) Rating Reiterated at Weiss Ratings

Key Points

• Zura Bio's stock rating was reiterated as "sell (D-)" by Weiss Ratings, indicating a negative outlook on the company's performance.
• Despite the sell rating from Weiss, other analysts have different views, with Chardan Capital assigning a "buy" rating and a price target of $10.00.
• The company reported earnings per share of ($0.17) for the last quarter, beating estimates by $0.02, while the stock trades at $3.75 with a 12-month low of $0.97.

Zura Bio (NASDAQ:ZURA - Get Free Report)'s stock had its "sell (d-)" rating reiterated by stock analysts at Weiss Ratings in a note issued to investors on Tuesday,Weiss Ratings reports.

A number of other analysts have also commented on the stock. Chardan Capital reissued a "buy" rating and issued a $10.00 price objective on shares of Zura Bio in a research report on Tuesday, September 30th. HC Wainwright cut their price objective on shares of Zura Bio from $3.00 to $2.00 and set a "neutral" rating on the stock in a research report on Tuesday, August 19th. Finally, Oppenheimer cut their price objective on shares of Zura Bio from $17.00 to $16.00 and set an "outperform" rating on the stock in a research report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $11.60.

Zura Bio Price Performance

ZURA traded down $0.12 during trading on Tuesday, reaching $3.75. The company had a trading volume of 600,181 shares, compared to its average volume of 872,076. Zura Bio has a 12 month low of $0.97 and a 12 month high of $5.07. The business's fifty day moving average price is $2.39 and its 200 day moving average price is $1.65. The company has a market cap of $243.50 million, a P/E ratio of -5.33 and a beta of 0.25.

Zura Bio (NASDAQ:ZURA - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. As a group, sell-side analysts predict that Zura Bio will post -0.65 EPS for the current fiscal year.

Institutional Trading of Zura Bio

Large investors have recently modified their holdings of the stock. Allostery Investments LP lifted its stake in Zura Bio by 44.2% during the 1st quarter. Allostery Investments LP now owns 2,329,384 shares of the company's stock valued at $3,005,000 after acquiring an additional 714,258 shares in the last quarter. ADAR1 Capital Management LLC grew its holdings in shares of Zura Bio by 34.9% during the first quarter. ADAR1 Capital Management LLC now owns 2,801,184 shares of the company's stock worth $3,614,000 after purchasing an additional 723,933 shares in the last quarter. Armistice Capital LLC grew its holdings in shares of Zura Bio by 2.4% during the first quarter. Armistice Capital LLC now owns 1,536,000 shares of the company's stock worth $1,981,000 after purchasing an additional 36,000 shares in the last quarter. Forefront Analytics LLC boosted its stake in Zura Bio by 101.6% in the first quarter. Forefront Analytics LLC now owns 108,308 shares of the company's stock worth $140,000 after buying an additional 54,574 shares in the last quarter. Finally, Nuveen LLC bought a new stake in Zura Bio in the first quarter valued at approximately $76,000. Institutional investors and hedge funds own 61.14% of the company's stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.